Naslov
The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey

Autori
Potpara, Tatjana S. ; On behalf of the BALKAN-AF Investigators ; Trendafilova, Elina ; Dan, Gheorghe-Andrei ; Goda, Artan ; Kusljugic, Zumreta ; Manola, Sime ; Music, Ljilja ; Gjini, Viktor ; Pojskic, Belma ; Popescu, Mircea Ioakim ; Georgescu, Catalina Arsenescu ; Dimitrova, Elena S. ; Kamenova, Delyana ; Ekmeciu, Uliks ; Mrsic, Denis ; Nenezic, Ana ; Brusich, Sandro ; Milanov, Srdjan ; Zeljkovic, Ivan ; Lip, Gregory Y. H.

Izvornik
Advances in Therapy (0741-238X) 34 (2017), 8; 2043-2057

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Adherence to guidelines ; Atrial fibrillation ; Balkan Region ; Bleeding risk ; Clinical practice ; Evidence-based approach ; General cardiology ; Oral anticoagulation ; Stroke prevention ; Stroke risk.

Sažetak
Abstract Introduction: Data on management of atrial fibrillation (AF) in the Balkan Region are scarce. To capture the patterns in AF management in contemporary clinical practice in the Balkan countries a prospective survey was conducted between December 2014 and February 2015, and we report results pertinent to the use of non-vitamin K antagonist oral anticoagulants (NOACs). Methods: A 14-week prospective, multicenter survey of consecutive AF patients seen by cardiologists or internal medicine specialists was conducted in Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Montenegro, Romania, and Serbia (a total of about 50 million inhabitants). Results: Of 2712 enrolled patients, 2663 (98.2%) had complete data relevant to oral anticoagulant (OAC) use (mean age 69.1 ± 10.9 years, female 44.6%). Overall, OAC was used in 1960 patients (73.6%) of whom 338 (17.2%) received NOACs. Malignancy [odds ratio (OR), 95% confidence interval (CI) 2.06, 1.20-3.56], rhythm control (OR 1.64, 1.25-2.16), and treatment by cardiologists were independent predictors of NOAC use (OR 2.32, 1.51-3.54) [all p < 0.01)], whilst heart failure and valvular disease were negatively associated with NOAC use (both p < 0.01). Individual stroke and bleeding risk were not significantly associated with NOAC use on multivariate analysis. Conclusions: NOACs are increasingly used in AF patients in the Balkan Region, but NOAC use is predominantly guided by factors other than evidence-based decision-making (e.g., drug availability on the market or reimbursement policy). Efforts are needed to establish an evidence-based approach to OAC selection and to facilitate the optimal use of OAC, thus improving the outcomes in AF patients in this large region.

Izvorni jezik
Engleski

POVEZANOST RADA